<DOC>
	<DOCNO>NCT02299960</DOCNO>
	<brief_summary>The main purpose study analyse test-retest-reliability functional quantification endothelial dysfunction puls-amplitude-tonometry patient heart failure preserved/reduced ejection fraction , pulmonary hypertension , arterial hypertension diabetic nephropathy . In group , test-retest-reliability circulate endothelial cell well test-retest reliability non invasive cardiac output Monitoring observe analyse .</brief_summary>
	<brief_title>Measurement Endothelial Function Cardiac Output : New Methods</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Clinically stable last 4 week ( HFrEF : 7 day ) Signed consent form HFpEF : BaselineEchocardiography : hospitalization &lt; = 12 month diagnosis heart failure E/E ' &gt; 8 E ' &lt; 8 cm/s BNP &gt; = 100pg/ml NTproBNP &gt; = 300pg/ml last 6 month LAVI &gt; 28 ml/m² E/E ' &gt; 8 E ' &lt; 8cm/s PAPsys &gt; 40mmHg E/E ' &gt; 8 E ' &lt; 8 cm/s Possibility take part cardiac stress test Heart failure NYHA IIII Sinus rhythm Max . O2uptake exertion &lt; 20ml/kgBW/min HFrEF HFrEF due ischemic nonischemic reason NYHA IIII Individually optimize stable pharmacological therapy ( include betablocker , ACEInhibitor , AT1antagonist , aldosteroneantagonist ) EF &lt; =45 % , Simpson Biplan PH NICEClassification 2013 I/II PAH &gt; = 25 mmHg Precapillary PAH : Wedgepressure &lt; = 15 mmHg , CO normal low Postcapillary PAH : Wedgepressure &gt; = 15 mmHg , CO normal low Diabetic nephropathy : Diabetes mellitus Type 2 oral Insulin therapy one following : Diabetic nephropathy diagnose ( anamnesis ) Macroalbuminuria : Urine Albumine/Creatinineratio &gt; 300mg/g Creatinine ( &gt; 34mg/mmol ) 2 3 test Urine morning GFR &lt; 90ml/min/1.73m² ( CKDEPI ) Microalbuminuria : 30300mg/g Creatinine ( &gt; =3.4 mg/mmol &lt; 34mg/mmol ) test GFR &lt; 90 ml/min/1.73m² diabetic retinopathy AH : Hypertension diagnose least 6 month except structural heart disease : EF &gt; 55 % sign HFpEF No symptom coronary heart disease Possibility take part cardiac stress test Stable pharmacologic therapy Hypertension least 4 week Systolic blood pressure &lt; 140 mmHG Screening Patient incapable contract Angina pectoris &gt; CCS II Coronary Intervention last 4 week schedule Intervention/Bypass Myocardial infarction last 3 month Stroke last 3 month Valvular heart disease &gt; II° Cardiomyopathy due Infiltrate/hypertrophic obstruction ( e.g . HOCM , Amyloidosis ) Congenital complex heart disease Active myocarditis Significant lung disease Significant Cardiac dysrhythmia Scheduled change medication time study ( Scheduled ) heart transplant Cardiac resynchronisation therapy last three month ICD/Pacemakerimplant last 4 week Uncontrolled Hyper/Hypotension ( &gt; 180mmHg , &lt; 95mmHg ) Patient take part Rehabilitation program Diagnosed Malignant disease disease life expectancy &lt; 1 year Anemia Hb &lt; 10mg/dl Untreated significant thyroid disease HFpEF , Hypertension PH : Patient incapable cardiac stress test ( e.g . orthopedic Problems ) Significant change cardiovascular Status two week study Instable cardiopulmonary Status last four week HFrEF : I.v . Treatment inotropic drug diuretic last 7 day Screening Myocardial infarction last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>EndoPAT</keyword>
	<keyword>NICOM</keyword>
	<keyword>circulate endothelial cell</keyword>
</DOC>